PERRIGO Co plc (PRGO) Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Perrigo Company plc NYSE:PRGO Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $2.2B
Div Yield 7.33%
AH Close $15.82 +0.00% vs close
AH Close $15.82 +0.00% vs close
Mkt Cap $2.2B
Div Yield 7.33%
All Press Release SEC Filings News
Press Release ⚠ 1
Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026
Perrigo announced it will release third quarter 2026 financial results on Wednesday, November 4, 2026, with a conference call at 8:30 a.m. ET.
The call will be hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra, with a live webcast and replay available through November 11.
This is a routine scheduling notice with no financial results; note the company is still led by an interim CEO.
• 5d ago AI analysis › News
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
zacks.com • 1mo ago Press Release
Perrigo to Attend the Barclays Global Consumer Conference
Perrigo executives Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference.
The event is set for Thursday, September 10, 2026, offering an opportunity for management to engage with the investment community.
No specific presentation materials or new financial guidance were provided in the release.
• 1mo ago AI analysis › News
PRGO or NEOG: Which Is the Better Value Stock Right Now?
zacks.com • 2mo ago News
Should Value Investors Buy Perrigo (PRGO) Stock?
zacks.com • 2mo ago News
Perrigo: The Rebound Is Just Getting Started
seekingalpha.com • 2mo ago News
PRGO vs. NEOG: Which Stock Is the Better Value Option?
zacks.com • 2mo ago News
Are Investors Undervaluing Perrigo (PRGO) Right Now?
zacks.com • 2mo ago News
Perrigo Q2 Earnings Call Highlights
marketbeat.com • 2mo ago News
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
zacks.com • 2mo ago News
Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago SEC Filing ● Major ⚠ 8
PRGO: 10-Q · periodic report
Perrigo reported Q2 2026 net sales of $1,022.8 million, down from $1,056.3 million a year earlier, but swung to net income of $74.5 million ($0.54 basic EPS) from a year-ago loss. The first half still produced a net loss of $324.1 million (diluted EPS -$2.33), driven by $331.8 million of impairment charges including a $330.8 million goodwill impairment that fully wrote off the Infant Formula and Oral Care reporting units and reduced Women's Health goodwill by $77.4 million.
CEO Patrick Lockwood-Taylor resigned effective immediately on June 7, 2026, with board member Albert A. Manzone appointed Interim President and CEO. The board also expanded from 8 to 10 members with the June 30 appointments of Salman Amin and Omer Gajial.
Perrigo closed the sale of its Dermacosmetics business on April 30, 2026 for $362.9 million net of cash, booking a $129.5 million pre-tax gain, and used proceeds with an amended $1.0 billion revolver (due 2031) to retire its Term A loans and repay $335.0 million of borrowings. Total debt stands at $3,294.8 million against $399.7 million of cash, with credit ratings of Ba3/B+/BB and negative outlooks at Moody's and Fitch.
Watch items include negative operating cash flow of $31.0 million for the first half, a February 2026 FDA Form 483 at the Wisconsin infant formula facility, the DOJ's appeal of the $134.1 million IRS refund case (with potential incremental exposure of $25-128 million), and the ongoing strategic review of the infant formula business.
SEC 10-Q • 2mo ago AI analysis › News
Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say
zacks.com • 2mo ago News
Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates
zacks.com • 2mo ago Press Release ⚠ 3
Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations
Perrigo reported Q2 2026 net sales of $1.02 billion, down 3.2% year-over-year, while reported diluted EPS rose to $0.63 from $0.00 in the prior year due to a gain on the Dermacosmetics divestiture.
Underlying business performance was softer, with adjusted EPS declining 12.3% to $0.50 and core revenue falling 3.1% amid ongoing category softness and unfavorable mix.
Management reaffirmed its full-year 2026 outlook for adjusted EPS of $2.00 to $2.30, expecting a sequentially stronger second half driven by operational execution and easing under absorption.
• 2mo ago AI analysis › Press Release
Perrigo Announces Quarterly Dividend
Perrigo's Board of Directors declared a quarterly dividend of $0.29 per share, representing an annualized rate of $1.16.
The dividend is payable on September 15, 2026 to shareholders of record at the close of business on August 28, 2026.
The company continues to focus on its pure-play self-care model, leveraging store brand cash flow to support branded products like Opill and Mederma.
• 2mo ago AI analysis › Press Release
Perrigo to Present at the Canaccord 46th Annual Growth Conference
Perrigo executives are scheduled to present at the Canaccord 46th Annual Growth Conference.
Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will present on Wednesday, August 12th at 10:30 AM EDT.
The webcast will be available on the Perrigo investor relations website.
• 2mo ago AI analysis › Press Release
Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026
Perrigo Company plc announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026.
The company will host a conference call at 8:30 a.m. EST to discuss the results, hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra.
A live webcast will be available on the Perrigo investor relations website, with a replay accessible until August 12.
• 3mo ago AI analysis › SEC Filing
PRGO: 8-K/A · leadership change
Perrigo Company plc filed an amendment to its Form 8-K to disclose the employment agreement for Interim President and Chief Executive Officer Albert A. Manzone. The agreement, effective July 3, 2026, outlines the terms of Mr. Manzone's service following his appointment on June 7, 2026.
The employment contract sets a fixed term ending December 31, 2026, with a provision for the Board to extend his employment on a month-to-month basis for up to 90 days if a permanent CEO is not appointed by year-end. Mr. Manzone will receive an annual base salary of $1,270,000.
Additionally, the agreement includes a one-time special cash bonus of $250,000 subject to performance metrics and a restricted stock unit grant with a fair value of $2,500,000. The RSUs vest upon the earlier of one year, the hiring of a permanent CEO, or a change of control.
SEC 8-K/A • 3mo ago SEC Filing
PRGO: 8-K · leadership change
Perrigo Company plc reinstated its Executive Committee Severance Policy on June 29, 2026, reversing a termination that occurred in January 2020. The policy is effective during a specific transition period related to the change in Chief Executive Officer.
The policy covers executive officers, excluding the Interim CEO and the incoming successor, spanning from June 7, 2026, until 12 months after the new CEO commences employment. This timeline is anchored to the succession following former CEO Patrick Lockwood-Taylor.
Participating executives entitled to a qualifying termination will receive 1.5 times their base salary and target bonus paid over 18 months. Additional benefits include employer-paid COBRA premiums, a pro-rated performance bonus, and career transition assistance, contingent upon a release of claims and adherence to non-compete clauses.
SEC 8-K • 3mo ago AI analysis › Press Release
Perrigo Announces Appointment of Two New Independent Directors to Board
Perrigo appointed Salman Amin and Omer Gajial as independent directors to its Board, effective June 30, 2026.
Mr. Amin brings over 30 years of experience, most recently as CEO of pladis Global and previously at SC Johnson, PepsiCo, and Procter & Gamble.
Mr. Gajial currently serves as CEO of GoTo Foods and was formerly Executive Vice President at Albertsons Companies.
• 3mo ago AI analysis › News
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com • 4mo ago News
Perrigo CEO Ousted Over Personal Conduct
wsj.com • 4mo ago Press Release
Perrigo Announces Leadership Transition
Albert A. Manzone, a current director at Syntec Optics Holdings, has been appointed Interim President and CEO of Perrigo Company plc.
He succeeds Patrick Lockwood-Taylor, who resigned immediately following a board determination that his personal conduct was inconsistent with the Company's Code of Conduct, though unrelated to business operations.
Perrigo's board has initiated a comprehensive search for a permanent successor while reaffirming its full-year 2026 financial outlook.
• 4mo ago AI analysis › News
Perrigo: This 11% Yielder Should Cut The Dividend
seekingalpha.com • 4mo ago News
Why Is Perrigo (PRGO) Down 9% Since Last Earnings Report?
zacks.com • 4mo ago Press Release
Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
Perrigo Company plc announced that CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference.
The presentation is scheduled for Tuesday, June 9th at 10:30 AM EDT and will be available via webcast on the company's investor relations website.
This is a standard investor relations calendar update with no new operational or financial disclosures.
• 5mo ago AI analysis › Press Release ⚠ 3
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
Perrigo reported Q1 Core adjusted EPS of $0.40, topping expectations, while total revenue declined 7.2% year-over-year to $969 million.
Results were weighed down by a non-cash goodwill impairment charge of $330.8 million and lower consumption across U.S. and European markets, though Specialty Care segment sales grew.
The company maintained its full-year 2026 outlook and completed the sale of its Dermacosmetics business for roughly €306 million in upfront cash to reduce debt.
• 5mo ago AI analysis › Press Release ● Major
Perrigo Completes Divestiture of Dermacosmetics Business
Perrigo completed the sale of its Dermacosmetics business to Karo Healthcare for €305.6 million upfront, plus up to €27 million in milestone payments.
The divested unit generated approximately €120 million in net sales in 2025 and represented 5% of adjusted operating income.
Net proceeds will be used primarily to reduce debt, advancing the company's 'Three-S plan' to streamline its portfolio.
• 5mo ago AI analysis › Press Release
Perrigo Announces Quarterly Dividend
Perrigo's Board of Directors declared a quarterly dividend of $0.29 per share, which equates to an annualized rate of $1.16 per share.
The dividend is payable on June 16, 2026, to shareholders of record as of the close of business on May 29, 2026.
• 5mo ago AI analysis › Press Release
Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026
prnewswire.com • 6mo ago 
